Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant by Franck, S.E. (Sanne) et al.
E-Mail karger@karger.com
 Original Paper 
 Neuroendocrinology 2017;105:44–53 
 DOI: 10.1159/000448429 
 Somatostatin Receptor Expression in 
GH-Secreting Pituitary Adenomas Treated 
with Long-Acting Somatostatin Analogues in 
Combination with Pegvisomant 
 Sanne E. Franck  a    Federico Gatto  a    Aart Jan van der Lely  a    
Joseph A.M.J.L. Janssen  a    Alof H.G. Dallenga  b    A. Paul Nagtegaal  c    
Leo J. Hofland  a    Sebastian J.C.M.M. Neggers  a 
 a   Endocrinology Section, Department of Internal Medicine, and Departments of  b   Neurosurgery and 
 c   Otorhinolaryngology, Pituitary Center Rotterdam, Erasmus University Medical Center Rotterdam,  Rotterdam , 
The Netherlands
 
to achieve insulin-like growth factor I (IGF-I) normalization in 
relation to the SSTR expression.  Materials and Methods: At 
our Pituitary Center Rotterdam, we selected acromegalic pa-
tients who underwent transsphenoidal neurosurgery. All pa-
tients were eventually treated with LA-SSA/PEGV combina-
tion therapy during their medical history. SSTR2 and SSTR5 
expression in somatotroph adenoma tissues was deter-
mined using immunohistochemistry.  Results: Out of 39 so-
matotroph adenoma tissue samples, 23 were drug-naive,
9 received pretreatment with LA-SSA and 7 LA-SSA/PEGV 
combined treatment. SSTR2 expression was significantly 
higher in treatment-naive compared to combined treatment 
somatotroph adenomas (p = 0.048), while SSTR5 expression 
did not differ. Noteworthy, SSTR2 expression in naive so-
matotroph adenoma tissues was inversely correlated with 
the required PEGV dose to achieve IGF-I normalization dur-
ing postsurgical medical treatment (ρ = –0.538, p = 0.024). 
 Conclusion: In our specific cohort, the SSTR2 expression was 
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 Abstract 
 Background: Growth hormone-secreting pituitary adeno-
mas (somatotroph adenoma) predominantly express so-
matostatin receptors (SSTRs) subtypes 2 and 5. Higher SSTR2 
expression on somatotroph adenomas results in a better re-
sponse to somatostatin analogues (SSAs), which preferen-
tially bind, but also downregulate, SSTR2. The effect of the 
combined treatment with SSAs and the GH receptor antago-
nist pegvisomant (PEGV) on SSTR expression in somatotroph 
adenomas is currently unknown.  Aim of the Study: To assess 
SSTR2 and SSTR5 expression in three groups of somatotroph 
adenomas: drug-naive, treated with long-acting (LA) SSA 
monotherapy, or LA-SSA/PEGV combination therapy before 
surgery. Additionally, we evaluated the required PEGV dose 
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lower in patients pretreated with LA-SSA/PEGV compared to 
the drug-naive acromegalic patients. Additionally, the SSTR2 
expression in treatment-naive somatotroph adenoma tis-
sues was inversely correlated with the required PEGV dose 
to achieve IGF-I normalization.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Growth hormone-secreting pituitary adenomas (so-
matotroph adenomas) express different subtypes of so-
matostatin receptors (SSTRs), predominantly SSTR sub-
types 2 (SSTR2 ) and 5 (SSTR5)  [1] , which play a major 
role in reducing GH secretion and thereby insulin-like 
growth factor I (IGF-I) levels. Long-acting somatostatin 
analogues (LA-SSAs) have a high binding affinity for 
SSTR2 and a moderate affinity for SSTR5. According to 
current guidelines, LA-SSAs are considered to be the 
first-line medical treatment modality after unsuccessful 
surgery as well as primary treatment option in selected 
cases  [2, 3] . However, a number of studies published on 
the efficacy of LA-SSAs in acromegaly show that LA-SSA 
treatment alone fails to reach complete normalization of 
IGF-I levels in about 50% of the cases. A recent meta-
analysis reported an average control rate of 56% and 55% 
for GH and IGF-I normalization, respectively, during 
monotherapy with LA-SSA  [4] . However, due to selection 
bias, this efficacy rate is probably an overestimation. In 
unselected treatment-naive patients, an LA-SSA efficacy 
rate of 40% seems to be more common  [5, 6] . Tumor 
shrinkage with LA-SSA was observed in 63–75% of these 
primary-treated patients  [6] .
 The expression of SSTR2 on somatotroph adenoma 
cell membrane is significantly and positively correlated 
with the efficacy of LA-SSAs in suppressing GH and
IGF-I levels in vitro, and it is also associated with IGF-I 
normalization in acromegalic patients  [7–11] . In this 
light, a recent study from our group showed that an 
SSTR2 immunoreactivity score (IRS) of at least 5 had a 
sensitivity of 86% and a specificity of 91% in predicting 
IGF-I control during adjuvant LA-SSA treatment  [9] . Ad-
ditionally, SSTR2 expression and tumor volume reduc-
tion after LA-SSA treatment are positively correlated  [11, 
12] . Moreover, tumors that are partial responders and 
nonresponders to monotherapy with LA-SSAs seem to 
have lower SSTR2 mRNA expression and higher SSTR5 
mRNA expression compared to full responders on LA-
SSAs  [13] . An effective treatment option to normalize 
IGF-I levels in partial-responder patients is the addition 
of the GH receptor antagonist pegvisomant (PEGV) to 
first-line medical treatment with LA-SSA  [14, 15] . To the 
best of our knowledge, the expression of SSTR2 and 
SSTR5 on somatotroph adenoma tissues from acrome-
galic patients treated with PEGV (together with LA-SSAs) 
before surgery is currently unknown.
 Based on the finding that the response to LA-SSA 
treatment is mainly driven by the expression of SSTR2, a 
reduced expression of SSTR2 in untreated somatotroph 
adenomas at baseline, probably necessitates combined 
treatment because of (partial) resistance to LA-SSA treat-
ment. However, we cannot exclude feedback mechanisms 
like the drop in IGF-I levels during medical treatment and 
an associated increase in hypothalamic growth hormone-
releasing hormone (GHRH) levels, which theoretically 
also can influence the expression of SSTR2 and SSTR5 on 
the somatotroph adenoma cell membrane. To investigate 
the effects of the addition of PEGV to LA-SSAs on SSTR 
expression, we assessed the expression of SSTR subtypes 
2 and 5 in three groups of acromegalic patients: drug-
naive (naive group), treated with long-acting SSA mono-
therapy (mono-LA-SSA group) before surgery, and treat-
ed with the combination of LA-SSAs and PEGV (com-
bined group) before surgery. Since all patients included 
in the present study received LA-SSA/PEGV combined 
treatment during their clinical history, we were able to as-
sess the required PEGV dose (added to LA-SSAs) needed 
after surgery to achieve the normalization of IGF-I levels. 
Therefore, we additionally evaluated the required PEGV 
dose in relation to the expression of SSTR2 and SSTR5, in 
order to observe indirectly the partial resistance to LA-
SSA. The underlying hypotheses were (1) various medi-
cal pretreatment modalities could differently affect the 
SSTR2 and SSTR5 expression on somatotroph adenomas, 
and (2) the SSTR expression could affect postsurgical 
PEGV dosing in combination with LA-SSA.
 Methods 
 Patient and Somatotroph Adenoma Tissue Selection 
 Data collection of acromegalic patients was performed at our 
Rotterdam Pituitary Center, and a retrospective evaluation was car-
ried out. We used a database including acromegalic patients which 
were all eventually treated with PEGV in combination with LA-SSA 
(n = 141), and we selected those patients who underwent transsphe-
noidal neurosurgery (n = 66), representing a total of 71 transsphe-
noidal surgeries. Five patients underwent a second surgery; of these 
patients, we only included the tissue samples of the first surgery. 
Besides medical history data, a somatotroph adenoma paraffin-em-
bedded tissue sample had to be available in order to perform im-
munohistochemistry. We selected 39 somatotroph adenoma tis-
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sues obtained from 39 patients. A flowchart representing the selec-
tion procedure of the somatotroph adenoma tissues for our study 
is depicted in  figure 1 . No patient underwent radiotherapy before 
surgery. Three groups of different medical pretreatment modalities 
before surgery were identified: drug-naive patients, patients on 
monotherapy with LA-SSAs and patients treated with LA-SSAs in 
combination with PEGV.  Table 1 shows patient characteristics of 
the three pretreatment groups before surgery. The mono-LA-SSA 
group was treated with LA-SSAs for a median of 6 months; the 
combined group was treated for a median of 20 months with LA-
SSAs and for a median of 13 months with PEGV before surgery. 
PEGV treatment was added to the highest dose of LA-SSA by week-
ly injections. For starting doses of PEGV and the protocol of PEGV 
dose titration to achieve normal IGF-I levels see Neggers et al.  [14] . 
Magnetic resonance imaging was used to assess tumor volume as 
macro- versus microadenomas at time of diagnosis.
 All patients selected for this study were eventually treated with 
LA-SSA in combination with PEGV after surgery and were subdi-
vided into partial and full responders to monotherapy with LA-
SSAs. Most of the patients included in this study were partial re-
sponders to LA-SSAs (n = 31) and were considered to have a min-
imal decrease of 15% in their GH and IGF-I levels and still have 
elevated IGF-I serum levels [>1.2× upper limit of normal (ULN)] 
after at least 6 months on the highest dose of LA-SSAs (Sandostatin 
LAR 30 mg or lanreotide autogel 120 mg every 28 days). These pa-
tients required PEGV in combination with LA-SSA in order to 
achieve normalized IGF-I levels. Partial responders had a median 
IGF-I decrease of –28.4% (interquartile range, IQR: –21.2 to –43.4) 
after LA-SSA monotherapy. Full responders to LA-SSAs (n = 8) 
achieved normal IGF-I levels during monotherapy with LA-SSAs 
and received PEGV during a clinical trial aimed to investigate as-
pects of quality of life  [16] . Full responders had a median IGF-I 
decrease of –61.9% (IQR: –53.5 to –67.3) after LA-SSA monother-
apy. In order to subdivide the total cohort into partial and full re-
sponders, the response to monotherapy with LA-SSA could have 
been evaluated before or after surgery.  Table 2 provides general, 
biochemical and somatotroph adenoma characteristics of partial 
and full responders to the monotherapy with LA-SSAs. When in-
vestigating the required PEGV dose to achieve IGF-I normaliza-
tion in relation to the SSTR2 expression, we included only the par-
tial-responder patients, not pretreated before surgery, in order to 
achieve a clearer indication from a homogeneous cohort. Permis-
sion from the Institutional Review Board of the Erasmus Medical 
Center Rotterdam was obtained, and all patients gave their written 
informed consent.
 Hormone Assays 
 Serum IGF-I levels were measured with a radioimmunoassay 
[Medgenix Diagnostics, Fleurus, Belgium; intraassay coefficient of 
variation (CV) 6.1%, interassay CV 9.9%], an immunoradiometric 
assay (Diagnostic Systems Laboratories, Webster, Tex., USA, in-
traassay CV 3.9%, interassay CV 4.2%) and the Immulite 2000 as-
say, a solid-phase, enzyme-labelled chemiluminescent immuno-
metric assay (DPC Biermann GmbH/Siemens, Fernwald, Germa-
Excluded from this study:
Included in this study
n = 39
Surgery 1988–2013
n = 71
• No tissue available n = 13
• Tissue sample too small n = 8
• Tissue of a second surgery n = 5
• DA before surgery n = 3
• Medical treatment unknown n = 2
• Histological diagnosis inconclusive n = 1
Naive
n = 23
LA-SSA
n = 9
All patients were 
eventually treated with
LA-SSA + PEGV
LA-SSA + PEGV
n = 7
Moment of surgery
regarding medical
pretreatment
 Fig. 1. Flowchart of the selection procedure in this study. Patients 
who underwent transsphenoidal surgery and eventually were 
treated with LA-SSA in combination with PEGV, were selected 
and tissues were collected. The number of tissues (n), which rep-
resents the number of patients, as we excluded tissues from a sec-
ond surgery. DA = Dopamine agonist; Naive = no previous medi-
cal treatment; LA-SSA = long-acting somatostatin analogues; 
PEGV = pegvisomant. 
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ny; intraassay variability of 2–5%, interassay variability of 3–7%). 
IGF-I age-adjusted reference ranges were used in accordance with 
an earlier report  [17] . IGF-I levels were evaluated just before sur-
gery, during monotherapy of LA-SSA and after surgery when every 
patient was eventually treated with LA-SSA in combination with 
PEGV. Over time, IGF-I assays were replaced by one another. We 
therefore chose to express IGF-I levels only as upper limits of nor-
mal (ULN) and not as absolute values.
 Immunohistochemistry 
 Thirty-nine somatotroph adenoma tissues were available for 
hematoxylin staining and immunostaining of SSTR2 and SSTR5. 
Formalin-fixed paraffin-embedded tumor samples were cut into 
sequential 4-μm-thick sections and deparaffinized and stained us-
ing a fully automated Ventana BenchMark ULTRA stainer (Ven-
tana, Tucson, Ariz., USA) according to the manufacturers’ instruc-
tions at the Pathology Department. Binding of peroxidase-coupled 
antibodies was detected using 3,39-diaminobenzidine as a sub-
strate, and the sections were counterstained with hematoxylin. The 
rabbit monoclonal anti-sst 2 antibody (BioTrend, Köln, Germany) 
was used at a dilution of 1: 25, whereas the rabbit monoclonal anti-
sst 5 antibody at a dilution of 1: 50.
 Normal pancreatic tissue served as a positive control for both 
SSTR2 and SSTR5 staining. For negative controls, the primary an-
tibody was omitted. Immunostaining of the somatotroph adeno-
ma tissues was scored by a semiquantitative immunoreactivity 
scoring system (IRS)  [18] and is the product of the percentage of 
positive-stained cells (0: no positive cells; 1: <10%; 2: 10–50%;
3: 51–80%; 4: 80%) and the staining intensity (0: no staining;
1: weak staining; 2: moderate staining; 3: strong staining) ( fig. 2 ). 
IRS 3 IRS 6 IRS 12
H
E
SS
TR
2
SS
TR
5
 Fig. 2. Heterogeneous expression patterns of SSTR2 and SSTR5 on 
somatotroph adenomas scored by the immunoreactivity score 
(IRS). IRS 3 represents a low, IRS 6 an intermediate and IRS 12 a 
high SSTR2 and SSTR5 expression pattern. Photography was per-
formed during ×200 magnification. HE = Haematoxylin; SSTR2 = 
somatostatin receptor subtype 2; SSTR5 = somatostatin receptor 
subtype 5. 
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The IRS ranges between 0 and 12. The somatotroph adenoma tis-
sue scoring was performed by 2 independent investigators (S.E.F 
and F.G.), who were blinded to each other’s findings, patient char-
acteristics and their treatment regimes.
 Statistical Methods 
 Data are expressed as median (IQR). Differences between two 
subgroups were analyzed using an unpaired t test or the Mann-
Whitney U test (in case of nonparametric data). Differences be-
tween three independent subgroups were analyzed using one-way 
ANOVA or the Kruskal-Wallis test (in case of nonparametric 
data). Nominal variables were analyzed using Fisher’s exact test. 
Results of correlation analyses were expressed as Spearman’s rank 
correlation coefficients (rho). p values <0.05 (two-tailed) were 
considered statistically significant. Statistical analyses were per-
formed with SPSS version 20 (IBM SPSS Statistics for Windows, 
Armonk, N.Y., USA) and GraphPad Prism version 6 for Windows 
(GraphPad Software, San Diego, Calif., USA).
 Results 
 Patient Characteristics before Surgery 
 Patient characteristics before surgery are presented in 
 table 1 . Out of the 39 evaluated somatotroph adenoma 
tissue samples, 23 were collected during a drug-naive 
state, 9 during mono-LA-SSA therapy and 7 during LA-
SSAs combined with PEGV therapy. No significant dif-
ferences were present between the three medical pretreat-
ment groups before surgery when considering sex, tumor 
volume assessed as macro- versus microadenomas, IGF-I 
levels at diagnosis, age at time of surgery, IGF-I levels be-
fore surgery and the duration of LA-SSA treatment before 
surgery. IGF-I levels are expressed as xULN.
 Expression of SSTR2 and SSTR5 after Different 
Medical Pretreatment Options 
 The SSTR2 IRS in the naive group had a median of 6.0 
(2.0–12.0), the mono-LA-SSA group had a median of 6.0 
(6.0–12.0), and the group pretreated with LA-SSA and 
PEGV had a median of 2.0 (1.0–4.5) ( fig. 3 a). A pairwise 
comparison showed that the median SSTR2 IRS on so-
matotroph adenomas was statistically significantly higher 
in the treatment-naive group compared to the combined 
group (p = 0.048). We did not find any statistically sig-
nificant difference in the SSTR2 IRS between the treat-
ment-naive and mono-LA-SSA groups. However, a trend 
for a lower median SSTR2 IRS was observed in the com-
bined group when compared to the mono-LA-SSA group 
(p = 0.055).
 Table 1.  Patient characteristics – medical pretreatment at time of surgery
Naive Mono-LA-SSA LA-SSA + PEGV p value
Tissues 23 (59.0) 9 (23.1) 7 (17.9)
Baseline characteristics 
Males 13 (56.5) 7 (77.8) 4 (57.1) 0.652
Tumor volume – macro 22 (95.7) 9 (100) 6 (85.7) 0.379
Tumor volume – largest diametera, mm 27.5 (17.0 – 40.0) 26.5 (25.0 – 27.0) 14.5 (13.0 – 16.0) 0.061
IGF-I xULN at diagnosisb 2.8 (2.7 – 3.1) 3.8 (2.7 – 5.5) 3.1 (2.8 – 4.5) 0.247
Time of surgery
Age at time of surgery, years 43.2 (29.9 – 49.8) 43.8 (36.2 – 46.3) 43.2 (36.7 – 47.1) 0.773
IGF-I xULN level before surgery 2.7 (2.5 – 3.2) 2.6 (1.7 – 3.8) 1.9 (1.3 – 2.4) 0.098
Duration of LA-SSA before surgeryc, months n.a. 6.0 (4.0 – 9.0) 20.0 (18.5 – 24.0) 0.094
Immunohistochemistry 
SSTR2 IRSd 6.0 (2.0 – 12.0) 6.0 (6.0 – 12.0) 2.0 (1.0 – 4.5)
SSTR5 IRS 12.0 (7.0 – 12.0) 12.0 (6.0 – 12.0) 9.0 (9.0 – 12.0)
 Data are presented as n (%) or median (IQR). Naive = No previous medical treatment; LA-SSA = long-acting somatostatin analogues; 
PEGV = pegvisomant; IGF-I = insulin-like growth factor I; ULN = upper limit of normal; n.a. = not applicable; IRS = immunoreactivity 
score; SSTR2 = somatostatin receptor subtype 2; SSTR5 = somatostatin receptor subtype 5. a The largest diameter was missing in 56.5% 
of the patients in the naive group, 33.0% in the mono-LA-SSA group and 14.3% in the LA-SSA + PEGV group. b The IGF-I level expressed 
as ULN at baseline was missing in 21.7% of the patients in the naive group. In the other two groups all data were available. c The mono- 
LA-SSA group includes 7 patients that used the maximum dose of LA-SSA and 2 patients which used Sandostatin LAR 20 mg monthly 
for 5 and 6 months. All patients in the combined treatment group used the maximum dose of LA-SSA. d Scoring system which takes into 
account both the percentage of positive cells and the intensity of the staining.
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 The SSTR5 IRS in the naive group had a median of 12.0 
(7.0–12.0), the mono-LA-SSA group had a median of 12.0 
(6.0–12.0), and the group pretreated with LA-SSA and 
PEGV had a median of 9.0 (9.0–12.0). The SSTR5 IRS did 
not significantly differ between LA-SSA + PEGV treat-
ment and the other two groups ( fig. 3 b).
 Partial and Full Responders to Monotherapy with
LA-SSAs 
 All patients selected for this study were eventually 
treated with LA-SSAs combined with PEGV after sur-
gery and were subdivided into partial and full respond-
ers to monotherapy with LA-SSAs. Partial-responder 
12
10
8
6
4
2
0
Naivea Mono-LA-SSA
Naive vs. combined p = 0.048
Naive vs. mono 
p = 0.828
Mono vs. combined
p = 0.055
SS
TR
2 
IR
S
LA-SSA + PEGV
12
10
8
6
4
2
0
Naiveb Mono-LA-SSA
Naive vs. combined p = 0.598
Naive vs. mono 
p = 0.938
Mono vs. combined
p = 0.837
SS
TR
5 
IR
S
LA-SSA + PEGV
 Table 2. Patient characteristics – partial and full responders during monotherapy with LA-SSA
Partial LA-SSA responders Full LA-SSA responders p value
Tissues 31 (79.5) 8 (20.5)
Males 19 (61.3) 5 (62.5) 0.640
Age at time of surgery, years 43.2 (30.7 – 49.9) 43.5 (42.1 – 49.7) 0.306
Tumor volume – macro 30 (96.8) 8 (87.5) 0.372
Medical pretreatment before surgery
Naive 16 (51.6) 7 (87.5)
Mono-LA-SSA 8 (25.8) 1 (12.5) 0.225
LA-SSA + PEGV 7 (22.8) 0
IGF-I xULN before surgery 2.3 (1.8 – 3.2) 2.8 (2.4 – 3.2) 0.853
IGF-I xULN during mono-LA-SSAa 2.0 (1.5 – 2.3) 0.7 (0.5 – 0.8) ≤0.001
Data are presented as n (%) or median (IQR). Partial responders to LA-SSA were considered to have elevated serum IGF-I levels after 
at least 6 months on the highest dose of LA-SSAs and needed PEGV for disease control. Full responders to LA-SSA achieved normal 
IGF-I levels during monotherapy of LA-SSA and PEGV was added because of quality of life reasons during a clinical trial. Monotherapy 
of LA-SSA could have been administered to the patient before or after surgery. Naive = No previous medical treatment; LA-SSA = long-
acting somatostatin analogues; PEGV = pegvisomant; , IGF-I = insulin-like growth factor I; ULN = upper limit of normal. a In order to 
subdivide the total cohort into partial and full responders, the response of IGF-I levels to monotherapy with LA-SSA could have been 
evaluated before or after surgery.
 Fig. 3. SSTR2 and SSTR5 expression per medical pretreatment 
group.  a The SSTR2 IRS was significantly lower in the combination 
group compared to the naive group.  b The SSTR5 IRS was not sig-
nificantly different between the different medical pretreatment 
groups. SSTR IRS is expressed as median (interquartile range). 
Pretreatment groups before surgery were tested reciprocally with 
the Mann-Whitney U test (naive: n = 23; mono-LA-SSA: n = 9; 
LA-SSA + PEGV: n = 7). Naive = No previous medical treatment; 
LA-SSA = long-acting somatostatin analogues; PEGV = pegviso-
mant; IGF-I = insulin-like growth factor I; ULN = upper limit of 
normal; SSTR2 = somatostatin receptor subtype 2; SSTR5 = so-
matostatin receptor subtype 5; IRS = immunoreactivity score. 
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patients had elevated serum IGF-I levels after at least 6 
months on LA-SSAs and needed PEGV in combination 
with LA-SSAs in order to achieve normalized IGF-I lev-
els. Full responders to LA-SSA achieved normal IGF-I 
levels during monotherapy with LA-SSA. Patient char-
acteristics of partial (n = 31) and full responders (n = 8) 
to monotherapy with LA-SSA are presented in  table 2 . 
No major differences were observed between partial and 
full responders to monotherapy with LA-SSAs regard-
ing sex, age at time of surgery, tumor volume assessed as 
macro versus microadenomas, medical pretreatment 
before surgery and IGF-I xULN at time of surgery. IGF-
I xULN during monotherapy with LA-SSA was signifi-
cantly different, as we selected this variable. As for the 
SSTR expression at the time of surgery, when only par-
tial-responder patients were included, we observed that 
the SSTR2 and SSTR5 IRS followed a similar distribu-
tion between the medical pretreatment groups to the 
one shown in the previous paragraph. However, possi-
bly due to the loss of statistical power (8 patients less 
were included in the analysis), the difference in the 
SSTR2 IRS between the naive and the combined group 
was not significant anymore (p = 0.135) (see online
suppl. fig.  1; for all online suppl. material see www.
karger.com/doi/10.1159/000448429).
 IGF-I Levels and PEGV Dosing in Relation to the 
SSTR2 and SSTR5 Expression 
 IGF-I levels (xULN) during monotherapy with the 
highest approved dose of LA-SSAs were inversely corre-
lated with the SSTR2 expression (ρ = –0.495, p = 0.002,
n = 39;  fig. 4 ). The SSTR5 expression was not correlated 
with the IGF-I (xULN) during monotherapy with LA-
SSA (ρ = 0.145, p = 0.405, n = 39). As mentioned in the 
Methods section, when observing the required PEGV 
dose to achieve IGF-I normalization in relation to the 
SSTR2 and SSTR5 expression, we included only the par-
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Q  Fig. 4. IGF-I xULN during the highest dose of monotherapy with 
LA-SSA was inversely correlated with the SSTR2 expression 
(Spearman correlation analyses). LA-SSA = Long-acting so-
matostatin analogues; IGF-I = insulin-like growth factor I; ULN = 
upper limit of normal; SSTR2 = somatostatin receptor subtype 2; 
IRS = immunoreactivity score. 
 Fig. 5.  a The required PEGV dose (mg/week) in combination with 
the highest dose of LA-SSA needed to control IGF-I levels was in-
versely correlated with the expression of SSTR2 (Spearman corre-
lation analyses). This figure only contains partial responders to 
monotherapy with LA-SSA, and the SSTR expression was estimat-
ed during a drug-naive state (n = 16).  b The expression of SSTR5 
was not correlated with the required PEGV dose. PEGV = Pegvi-
somant; LA-SSA = long-acting somatostatin analogues; SSTR2 = 
somatostatin receptor subtype 2; IRS = immunoreactivity score. 
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tial-responder patients, not pretreated before surgery 
(drug-naive status). In this context, we observed that the 
required PEGV dose was inversely correlated with the 
SSTR2 expression (ρ = –0.538, p = 0.024, n = 16;  fig. 5 a), 
while it did not correlate with the SSTR5 expression (ρ = 
–0.071, p = 0.792, n = 16;  fig. 5 b). The correlation analyses 
of the medical pretreatment groups before surgery 
[monotherapy with LA-SSA (n = 9) and LA-SSA in com-
bination with PEGV (n = 7)], as described in the first part 
of this results section, did not reveal statistical signifi-
cance between the required PEGV dose and the SSTR2 
and SSTR5 expression. 
 Discussion 
 This is the first study aimed to investigate the expres-
sion of SSTR2 and SSTR5 in somatotroph adenoma tis-
sues of acromegalic patients treated with LA-SSAs in 
combination with PEGV. In our specific cohort, the com-
bined group (LA-SSA/PEGV) showed a lower median 
SSTR2 IRS at the time of surgery compared to the drug-
naive group, while the IRS of the SSTR5 was not different 
between the pretreatment groups. Additionally, we ob-
served that the required PEGV dose to achieve normal-
ization of IGF-I levels was inversely correlated with the 
SSTR2 expression, but not with the IRS of SSTR5 in drug-
naive acromegalic patients. In the following discussion, 
we focus on all the possible explanations for the finding 
that in our cohort the SSTR2 expression was lower in the 
combined group compared with the naive group. The 
most likely explanation for this finding is that somato-
troph adenomas (partially) resistant to LA-SSA, which 
need combined treatment, have lower SSTR2 expression 
at baseline. However, we cannot exclude that other fac-
tors, such as feedback mechanisms of the GH-IGF-I axis 
and the downregulation of SSTR2 due to prior LA-SSA 
treatment could affect the SSTR expression as well.
 As far as the GH-IGF-I axis feedback mechanisms play 
a possible role in the modulation of SSTR expression, we 
assume that GH itself does not have a direct effect on the 
modulation of SSTRs at the pituitary level during combi-
nation treatment, since PEGV blocks GH receptors also 
at the level of the pituitary  [19] . More complex is the pre-
diction of GHRH levels via the hypothalamus in the pres-
ence of PEGV treatment. PEGV generally causes a further 
elevation of serum GH levels  [20] , which could result in 
a decrease in GHRH via some areas in the hypothalamus 
and might consequently result in a downregulation of 
SSTR2. On the other hand, the drop of IGF-I and the as-
sociated increase in hypothalamic GHRH levels might 
have an influence on the expression of SSTR2 and SSTR5 
at the level of the somatotroph adenoma as well. In our 
study, IGF-I levels of patients treated with LA-SSA in 
combination with PEGV were relatively lower compared 
to the naive group. However, Park et al.  [21] reported that 
in spontaneous dwarf rats, the expression of all SSTR sub-
types was not directly influenced by exogenous IGF-I 
treatment. Moreover, in the same study, the authors ob-
served that GHRH has a direct stimulatory effect on 
SSTR2 expression, both in vivo and in vitro. If these ob-
servations can be extrapolated to humans, we could spec-
ulate that the decrease in IGF-I levels probably does not 
play a major role in the explanation of the observed de-
crease in SSTR2 expression during the combination treat-
ment, while the modulation of GHRH levels seems to be 
more involved. However, based on the current knowl-
edge, our results demonstrating a lower SSTR2 expres-
sion in the combined group compared to the naive group 
cannot clearly be explained by the effect of PEGV on the 
modulation of the GH-IGF-I-pituitary-hypothalamus 
axis. Finally, to the best of our knowledge, a direct effect 
of PEGV on SSTR expression has not been reported, al-
though it cannot be excluded a priori.
 The downregulation of cell surface SSTR2 by endoge-
nous somatostatin and LA-SSA treatment has been re-
ported in several studies  [7, 22, 23] , possibly through li-
gand-induced receptor internalization. Casar-Borota et al. 
 [7] demonstrated this downregulation of SSTR2 expres-
sion by LA-SSA therapy also in a randomized subset of 
acromegalic patients (n = 13 mono-LA-SSA, n = 13 direct 
surgery), to exclude a possible clinical selection bias. How-
ever, we did not observe a statistically significant differ-
ence in SSTR2 expression between the naive and mono-
LA-SSA pretreatment groups in our acromegaly cohort
(p = 0.828). A possible explanation for this finding may 
reside in the selection of our patient group. Indeed, our 
cohort is most likely represented by acromegalic patients 
with more disease activity, since they were all referred to 
us as a tertiary referral hospital and, most importantly, the 
majority of these patients needed PEGV in addition to 
LA-SSAs to normalize their IGF-I levels (n = 31). In this 
light, as shown in the result section, even the drug-naive 
group showed a relatively low SST2 IRS (median IRS 6, 
which means about 50% of moderately stained cells) com-
pared to the staining observed in a previous study using 
comparable techniques and scoring system (median IRS 
9)  [7] . This finding may result in a lower downregulation 
of SSTR2 after LA-SSA treatment alone and/or contribute 
to ‘mask’ the downregulation of a receptor pattern already 
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relatively low at baseline. However, considering all these 
limitations, we observed that the combined treatment 
group in our study had a lower SSTR2 IRS compared to 
the naive group. Noteworthy, the SSTR2 IRS was almost 
significantly different (p = 0.055) between the mono-LA-
SSA and combined groups. Furthermore, the duration of 
LA-SSA treatment was remarkably shorter in the mono-
LA-SSA group compared to the combined treatment 
group by a median difference of 14 months; however, this 
difference did not reach statistical significance. This dif-
ference could be a possible explanation (besides the con-
comitant treatment with PEGV) for the observed lower 
expression of SSTR2 in the combined treatment group 
compared to the mono-LA-SSA and naive groups. Thus, 
the lower expression of SSTR2 in the somatotroph adeno-
mas in the combined treatment group could simply be 
related to the fact that these patients necessitate combined 
treatment due to their (partial) resistance to LA-SSA treat-
ment. Therefore, we can hypothesize that these partial re-
sponders to monotherapy with LA-SSA already have a 
lower SSTR2 expression at baseline, which could be the 
reason why these patients need PEGV in addition to LA-
SSA for disease control. It has already been reported that 
full responders to LA-SSA have a significantly higher 
SSTR2 expression compared to partial LA-SSA respond-
ers  [9, 12] . Furthermore, for the first time, we observed 
that in drug-naive somatotroph adenomas, a lower SSTR2 
expression correlates with a higher required PEGV dose 
in order to achieve normalized IGF-I levels, which also 
reflects more severe disease activity. This observation may 
have clinical implications for the postoperative treatment 
of acromegalic patients and, therefore, represents an im-
portant finding of our study.
 The main limitations of this study are (1) the retro-
spective design, (2) the relative small sample size and
(3) the peculiar patient group in which the study has been 
conducted (all treated with combination medical therapy 
during their clinical history). However, this can be ex-
pected due to the rarity of acromegaly as well as the fact 
that only a subset of the patients is treated with LA-SSA 
in combination with PEGV. These limitations of the pres-
ent study could be overcome in the future by the design 
of a large prospective randomized study aimed to evalu-
ate the impact of different treatment modalities on SSTR 
expression. Furthermore, the assessment of IGF-I and 
GH levels can also be improved, and, in particular, GH 
measurement should be assessed by a noncommercial as-
say in order to distinguish between endogenous GH and 
PEGV, which has recently been introduced in our clinical 
practice.
 Conclusion 
 This is the first study that assessed the effect of the 
combined medical treatment with LA-SSAs and PEGV 
on SSTR expression in somatotroph adenoma tissues of 
acromegalic patients. In our specific cohort, the SSTR2 
expression was lower in patients pretreated with LA-SSA/
PEGV compared to the drug-naive acromegalic patients. 
This finding is in line with the evidence that LA-SSA/
PEGV-treated patients are usually (partially) resistant to 
LA-SSA treatment alone (depending on SSTR2 expres-
sion). Moreover, we observed that patients with a lower 
SSTR2 expression need a higher required PEGV dose in 
combination with LA-SSA to achieve normalized IGF-I 
levels after surgery, when assessed in drug-naive somato-
troph adenoma tissues.
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